← Leaderboards
Xinhui Wang
University Of Pittsburgh At Pittsburgh
$2,999,091
Attributed
$3,040,921
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $831.7K · FY2009–23$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,900,921 · 5
FDA$140,000 · 1
By mechanism
R01$2,229,935 · 2
R21$406,638 · 1
R03$264,348 · 2
R30$140,000 · 1
Top collaborators
- Dan Gabriel Duda1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Nirmala Sundarraj$4,169,469
- James L Funderburgh$10,362,544
- Marina Mata$1,595,659
- Stephen H Thorne$3,784,781
- Saumendra N Sarkar$6,788,497
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoIn VitroNeoplastic CellMalignant NeoplasmsTumorMouse ModelCancer CellOperative Surgical ProceduresDiagnosisDesignNormal Tissue MorphologyChemotherapyBaseSolid NeoplasmNovel TherapeuticsRadiationRadiation TherapyCancer Stem CellGenesResistanceBreast Cancer CellApoptosisAldehyde Dehydrogenases
Grant awards (14)
Prevention of post-therapy breast cancer metastasis$364,899
R01 · FY2023 · CA · contact PI
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer$383,100
R01 · FY2022 · DE · contact PI
Prevention of post-therapy breast cancer metastasis$364,898
R01 · FY2022 · CA · contact PI
Radiation and CSPG4-specifc CAR T cell based combinatorial therapy for the in vivo treatment of TNBC$83,660
R03 · FY2022 · CA
Prevention of post-therapy breast cancer metastasis$372,346
R01 · FY2021 · CA · contact PI
Prevention of post-therapy breast cancer metastasis$372,346
R01 · FY2020 · CA · contact PI
Prevention of post-therapy breast cancer metastasis$372,346
R01 · FY2019 · CA · contact PI
Development of biomarkers for trastuzumab-induced cardiotoxicity$70,000
R30 · FY2018 · FD · contact PI
Development of biomarkers for trastuzumab-induced cardiotoxicity$70,000
R30 · FY2017 · FD · contact PI
Improving Radiation Therapy For Pancreatic Cancer$220,632
R21 · FY2016 · CA · contact PI
Improving Radiation Therapy For Pancreatic Cancer$186,006
R21 · FY2015 · CA · contact PI
B7-H3 in prognosis and immunotherapy of pancreatic cancer$45,930
R03 · FY2010 · CA · contact PI
B7-H3 in prognosis and immunotherapy of pancreatic cancer$33,335
R03 · FY2010 · CA · contact PI
B7-H3 in prognosis and immunotherapy of pancreatic cancer$101,423
R03 · FY2009 · CA · contact PI